CSIMarket Company Name, Ticker, Customers, else..
 
Eupraxia Pharmaceuticals Inc   (NASDAQ: EPRX)
 
Price: $8.2800 $0.26 3.242%
Day's High: $8.479999542236328 Week Perf: -1.43 %
Day's Low: $ 8.14 30 Day Perf: 27.78 %
Volume (M): 199,651 52 Wk High: $ 9.32
Volume (M$): $ 0 52 Wk Avg: $6.90
Open: $8.14 52 Wk Low: $4.75



 Market Capitalization (Millions $) 331
 Shares Outstanding (Millions) 40
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -39
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 1

Business Description


The company utilizes debt financing to support its operations and may pursue acquisitions or strategic alliances to enhance its business. It depends on key collaborations and grants for development programs and is required to comply with evolving global data privacy, protection, and information security regulations, which may affect its operations and expenses.


   Company Address: 201-2067 Cadboro Bay Road Victoria 0 BC
   Company Phone Number: 590-3968   Stock Exchange / Ticker: NASDAQ EPRX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Eupraxia Pharmaceuticals Shows Promising Long-Term Efficacy in EoE Treatment and Achieves Industry-Leading Leverage R...

Published Fri, Nov 14 2025 9:50 AM UTC

Eupraxia Pharmaceuticals Progress in EoE Treatment: Eupraxia Pharmaceuticals has reported encouraging 52-week follow-up results from their RESOLVE clinical trial, focusing on their investigational therapy, EP-104GI, for Eosinophilic Esophagitis (EoE). This chronic immune system disease, characterized by an overabundance of eosinophils in the esophageal lining, can lead to s...
Personnel Announcements

Eupraxia Pharmaceuticals Unveils Cutting-Edge Solutions for Osteoarthritis Treatment at International Congress

Published Thu, Apr 11 2024 11:00 AM UTC


VICTORIA, BC, April 11, 2024 - Eupraxia Pharmaceuticals Inc. (Eupraxia or the Company) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs, has recently announced its participation in the Osteoarthritis Research Society Interna...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 4.03
PEG (TTM) -

Financial Strength Current
Quick Ratio 14.51
Working Capital Ratio 15.46
Leverage Ratio (MRQ) 0.05
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.03 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 2.02 $
Book Value 2.05 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.